Skip to Content

Cobicistat / Darunavir Dosage

Medically reviewed on August 8, 2017.

Applies to the following strengths: 150 mg-800 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

1 tablet orally once a day with food

-HIV genotypic testing is recommended before starting therapy in antiretroviral therapy-experienced patients.
-If HIV genotypic testing is not possible, this drug should be used in protease inhibitor-naive patients only.

Use: In combination with other antiretroviral agents, for the treatment of HIV-1 infection in therapy-naive and therapy-experienced patients without darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V)

Renal Dose Adjustments

No adjustment recommended.

Estimated CrCl less than 70 mL/min: Coadministration with tenofovir is not recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Comments: The components of this drug are highly protein-bound; significant removal via dialysis is not likely.

Other Comments

Administration advice:
-Administer with other antiretroviral agents.
-Administer didanosine 1 hour before or 2 hours after this drug (which is administered with food).
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

-General: HIV genotypic testing in antiretroviral therapy-experienced patients (before starting therapy)
-Hematologic: For bleeding in hemophiliacs (during therapy)
-Hepatic: Liver function (before starting and during therapy; more often in at-risk patients)
-Hypersensitivity: Patients with known sulfonamide allergy (after starting therapy)
-Metabolic: Serum phosphorus in patients with or at risk of renal dysfunction (when used with tenofovir)
-Renal: Estimated CrCl (before starting therapy); for renal safety (if serum creatinine increases more than 0.4 mg/dL from baseline); estimated CrCl, urine glucose, and urine protein (at baseline and routinely during therapy [when used with tenofovir])

Patient advice:
-Do not alter the dose or stop therapy without consulting physician.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.